Deciphera Pharmaceuticals DCPH
$ 25.59
0.0%
Annual report 2023
added 02-07-2024
Deciphera Pharmaceuticals Balance Sheet 2011-2024 | DCPH
Annual Balance Sheet Deciphera Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-57.6 M | -35.6 M | -56.2 M | - | -103 M | -292 M | -195 M | -55.8 M | -23.9 M | - | - | - | - |
Long Term Debt |
22.4 M | 25.9 M | 28 M | - | - | 1.11 M | 1.29 M | 1.48 M | 1.68 M | - | - | - | - |
Long Term Debt Current |
3.5 M | 3.24 M | 2.87 M | 2.46 M | 1.75 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 15.9 M | 12.8 M | 1.31 M | 194 M | 139 M | - | - | - | - |
Total Current Liabilities |
100 M | 86.5 M | 96.8 M | 70 M | 60 M | 22.7 M | 13.8 M | - | - | - | - | - | - |
Total Liabilities |
123 M | 112 M | 125 M | 98.8 M | 75.9 M | 35.6 M | 15.1 M | 199 M | 142 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.43 B | -1.23 B | -1.05 B | -754 M | -488 M | -296 M | -196 M | -146 M | -120 M | - | - | - | - |
Total Assets |
474 M | 454 M | 429 M | 642 M | 622 M | 316 M | 199 M | 58.9 M | 26.8 M | - | - | - | - |
Cash and Cash Equivalents |
83.5 M | 64.7 M | 87.1 M | 136 M | 120 M | 294 M | 197 M | 57.5 M | 25.8 M | - | - | - | - |
Book Value |
351 M | 342 M | 305 M | 544 M | 546 M | 280 M | 184 M | -140 M | -115 M | - | - | - | - |
Total Shareholders Equity |
351 M | 342 M | 305 M | 544 M | 546 M | 280 M | 184 M | -140 M | -115 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Deciphera Pharmaceuticals
2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
23.3 M | 24.2 M | 25 M | 25.9 M | 26.7 M | - | 27.2 M | 28 M | 27.2 M | 27.9 M | 28.4 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M | 11.3 M | 17.5 M | 16.9 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
116 M | 105 M | 109 M | 112 M | 102 M | - | 114 M | 125 M | 103 M | 93.9 M | 92.2 M | 98.8 M | 98.8 M | 98.8 M | 98.8 M | 75.9 M | 75.9 M | 75.9 M | 75.9 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 6.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.38 B | -1.33 B | -1.28 B | -1.23 B | -1.19 B | - | -1.1 B | -1.05 B | -966 M | -886 M | -816 M | -754 M | -754 M | -754 M | -754 M | -488 M | -488 M | -488 M | -488 M | -296 M | -296 M | -296 M | -296 M | -196 M | -196 M | -196 M | -196 M | -146 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
498 M | 510 M | 549 M | 454 M | 476 M | - | 385 M | 429 M | 483 M | 541 M | 595 M | 642 M | 642 M | 642 M | 642 M | 622 M | 622 M | 622 M | 622 M | 316 M | 316 M | 316 M | 316 M | 199 M | 199 M | 199 M | 199 M | 58.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
108 M | 81.4 M | 115 M | 64.7 M | 82.5 M | 110 M | 95.3 M | 87.1 M | 53.2 M | 90.9 M | 202 M | 136 M | 136 M | 136 M | 136 M | 120 M | 120 M | 120 M | 120 M | 294 M | 294 M | 294 M | 294 M | 197 M | 197 M | 197 M | 197 M | 57.5 M | - | - | - | 25.8 M | - | - | - | 770 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
382 M | 404 M | 440 M | 342 M | 374 M | - | 272 M | 305 M | 380 M | 447 M | 503 M | 544 M | 544 M | 544 M | 544 M | 546 M | 546 M | 546 M | 546 M | 280 M | 280 M | 280 M | 280 M | 184 M | 184 M | 184 M | 184 M | 52.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
382 M | 404 M | 440 M | 342 M | 374 M | 405 M | 272 M | 305 M | 380 M | 447 M | 503 M | 544 M | 544 M | 544 M | 544 M | 546 M | 546 M | 546 M | 546 M | 280 M | 280 M | 280 M | 280 M | 184 M | 184 M | 184 M | 184 M | -140 M | - | - | - | -115 M | - | - | - | -99.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency